|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
Platelet Antibodies, Indirect (IgG, IgM, IgA)
Test Code34327
CPT Codes
86023 (x3)
Preferred Specimen
2 mL serum
Minimum Volume
1 mL
Instructions
Collect 5 mL whole blood in a serum separator tube (SST) and separate serum before submitting
Transport Container
Plastic screw-cap vial
Transport Temperature
Refrigerated (cold packs)
Specimen Stability
Room temperature: Unacceptable
Refrigerated: 21 days
Frozen: Unacceptable
Refrigerated: 21 days
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Slight hemolysis, Moderate hemolysis, Gross hemolysis • Lipemia • Icterus, Any other anti-coagulant tube other than red-top
Methodology
Flow Cytometry (FC)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Tues, Sat; Report available: 3-6 days
Reference Range
| Platelet Ab, Indirect (IgG) | Negative |
| Platelet Ab, Indirect (IgM) | Negative |
| Platelet Ab, Indirect (IgA) | Negative |
Clinical Significance
The identification of circulating platelet antibodies is useful in order to identify immune-mediated platelet destruction. Disorders associated with immune platelet destruction include isoimmune neonatal thrombocytopenia, drug induced thrombocytopenia, drug sensitivities, allergies and post transfusion purpura. The destruction is either autoimmune, where a malfunction in the immune response results in the production of antibodies directed against 'self' platelet specific antigens; or else platelet destruction occurs when the patient received platelet-specific antibodies from an outside source such as a non-compatible blood transfusion or maternal transfer across the placental barrier. In either of the above situations, the detection of platelet antibodies is useful in order to determine if an immune basis is responsible for the thrombocytopenia observed clinically.
